AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

C-RAD

Legal Proceedings Report Jul 23, 2021

3148_iss_2021-07-23_f6f075f9-17ce-4a5c-865e-9877edc04dee.pdf

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

Former employee appeals verdict from the Stockholm Patent and Market court

The Stockholm Patent and Market court rejected a former employee claim on C-RAD for compensation. The court ruled that the former employee is not entitled to any compensation. The former employee has now appealed the verdict to the Svea Court of Appeal, which first shall decide if leave to appeal shall be granted.

The background is a lawsuit that was filed against C-RAD on May 9th, 2020 from a former employee, claiming compensation for an invention made during his employment at C-RAD. C-RAD strongly rejected the lawsuit and considered the compensation claim to be highly excessive, confirmed by the verdict from the Stockholm Patent and Market court, which found that no additional compensation shall be given.

This is the fourth in a series of court cases where the counterpart was either the same former employee or the company Beamocular AB (owned by the former employee and now in bankruptcy) for which he has been CEO. In all prior cases C-RAD has won.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email [email protected]

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-07-23 11:29 CEST.

Press Release 23 July 2021 11:29:00 CEST

Attachments

Former employee appeals verdict from the Stockholm Patent and Market court

Talk to a Data Expert

Have a question? We'll get back to you promptly.